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A CLINICAL ANALYSIS OF PATIENTS WITH EARLY-STAGE 
PROSTATE CANCER MANAGED WITHOUT INITIAL TREATMENT 
Gen KAWA， Yoshihito HIURA， Hisashi SATOH， Motohiko SUGI， 
Ichiro FUJITA， Naoki OGUCHI， Hiroshi Dor， Makoto ASHIDA， 
Hiyoshi OKADA， Koei MUGURUMA， Takashi MUROTA， Yasuki KOYAMA， 
Hiroshi KAWAMURA， Takashi OHARA， Mutsushi KAwAKITA and Tadashi MATSUDA 
From Kansai Medical University Prostate StuφGroup 
To search for a more suitable qualification indicating watchful waiting， we performed a 
retrospective study against early-stage prostate cancer patients managed without initial treatment. 
Thirty-three patients who had not been treated for more than 6 months after diagnosed as Tlc or T2 
prostate cancer were studied. The median values of total observation period， age at diagnosis， and 
initial PSA were 27.0 months， 69.0 years old， and 7.0 ng/ml， respectively. Among 28 patients who had 
had measurement ofserum PSA at least three times， seven patients showed a significant PSA elevation 
when transition of PSA level was analyzed using linear regression analysis. The other patients had 
been stable or PSA level declined. Between these two groups， there was no significant difference 
regarding age， initial PSA， PSA density， Gleason score， number of cancer-positive core， and cancer-
occupying rate in biopsy specimen. The median PSA doubling time in patients showing PSA 
elevation was 36.3 months. There were no patients showing PSA elevation among those with a 
cancer-occupying rate of less than 5%. Clinical disease progression was obviously observed in two 
cases although one did not show PSA elevation. During the observation period， treatment was 
eventually started in seven patients. The 5・yearrate of no treatment was 53.8% ・ Although a 
significant independent factor predicting the future treatment was not identified， univariate analysis 
revealed that the initial PSA value in patients undergoing treatment was significantly higher than that 
of those without treatment (p=0.032). We concluded that early-stage prostate cancer has clinical 
variability， and regular clinical evaluations as digital rectal examination should be performed when the 
patient was managed with watchful waiting 
(Acta Urol. Jpn. 48: 133-138， 2002) 











































































時 PSAの中央値は 7.0ng/ml (0.6 -65 ng 1m!)， 





中央値は 3(2-8) で，その内訳では 2-4が26
名， 5 -7が6名， 8ー 10が l名であった.組織学的
分化度別では，高分化型29例 (88%)，中分化型4例
(I2%) ，低分化型O例であった.























て，年齢，診断時 PSA値， PSA density， Gleason 
score，癌陽性コア数，癌占拠率について，いずれの
因子においても両者聞に有意な差は認められなかった
(Table 1).癌点拠率についてみると， 5 %以下のも
のでは PSA上昇例は認められなかった (Fig.2). こ
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Fig. 1. Transitions of serum PSA levels in patients showing PSA elevation (A) or not (B). 
Table 1. Clinical and pathological variables in patients who did or did not show 
PSA elevation 
Significant elevation of PSA 
Yes (n=7) No (n=21) p value 
Range Median Range 乱1edian
Age 6ト 85 69 54-87 70 0.47 
Initial PSA (ng/ml) 4.7 -34 7.3 0.6 -65 6.5 0.79 
PSA dinsity (ng/ml/c) 0.09-1.47 0.14 0.03-3.08 0.25 0.44 
Gleason score 2- 8 3 2- 6 3 0.51 
N umber of cancer positive core 1- 4 1- 5 0.63 
Cancer occupying rate 10-250 25 5-150 15 0.23 
• PSA e1evation 
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Fig. 2. Distribution of cancer-occupying rate. 
展を示唆する結果は認められなかった.残りの8例で
は，再生検では悪性所見は認められなかった.これら
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Fig. 3. Kaplan-Meier curve indicating rate of 
no treatment. 
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示されていない. Epsteinらは insignificantcancer 
















3例が PSA上昇群であった.これら 3例のうち 2例
河，ほか・前立腺癌 無治療経過観察
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